An observational study in Testicular Cancer, Survivorship and ASCVD, sponsored by Indiana University. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Indiana University · Observational
Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant
Testicular cancer (TC) is diagnosed in young adult males between 18-39 years old. There are late (≥10 years after treatment) atherosclerotic cardiovascular disease (ASCVD) events after cisplatin-based chemotherapy (CBCT) treatment in testicular cancer survivors (TCS), along with heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic syndrome. Early detection of ASCVD to direct preventive measures in young TCS is an unmet need as these patients typically fall short of traditional 40-45-year age-cut offs for ASCVD screening. ASCVD risk will be evaluated in TCS ≥ 5 years after treatment in three groups: 1)TCS exposed to CBCT, 2)TCS exposed to CBCT and bone marrow transplant (BMT), and 3)TCS cured with surgical resection/surveillance. The focus will be on detecting subclinical atherosclerosis in TCS using blood lipid biomarkers and advanced cardiac CT imaging.
295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.
This study's planned enrollment of 150 is above the median of 133 across 73 observational studies indexed under Testicular Neoplasms.
Browse Testicular Neoplasms studies →Indiana University is the lead sponsor of 986 studies on the registry; 198 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 118 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Testicular Cancer Patients who are disease free more than 5 years after diagnosis and treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TCS cured with surgical resection and surveillance (surgical/surveillance, Arm 1)
Diagnostic Test: Lipid profile · Diagnostic Test: Coronary artery assessment · Diagnostic Test: Hormone levels for hypogonadism
TCS treat with one or more lines of cisplatin-based chemotherapy
Diagnostic Test: Lipid profile · Diagnostic Test: Coronary artery assessment · Diagnostic Test: Hormone levels for hypogonadism
TCS treat with one or more lines of cisplatin-based chemotherapy, and who have undergone bone marrow transplant
Diagnostic Test: Lipid profile · Diagnostic Test: Coronary artery assessment · Diagnostic Test: Hormone levels for hypogonadism
Advanced lipid profile
Coronary artery assessment via CT scans
Hormone levels for hypogonadism
Lipid profile
HDL, LDL, Tg, Cholesterol, Novel Lipid biomarkers using blood draws
Time frame: More than 5 years after testicular cancer diagnosis, At recruitment
Coronary plaque assessment
Coronary calcium score, coronary artery anatomy and plaque assessment using CT scans
Time frame: More than 5 years after testicular cancer diagnosis, At recruitment
Hormone levels
Measurement of testosterone
Time frame: More than 5 years after testicular cancer diagnosis, At recruitment
Serum platinum
Measurement of residual serum platinum levels
Time frame: More than 5 years after testicular cancer diagnosis, At recruitment
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.